Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Journey Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Journey Medical's regulatory disclosures and financial reporting.
Journey Medical Corporation reported improved operating results for the quarter ended June 30, 2026. Total revenue was $18.5 million, up from $15.0 million a year earlier, driven mainly by Emrosi sales of $8.1 million and new supply and royalty revenue from its Cutia agreement. Net product revenue for the first six months rose to $33.8 million from $28.1 million, while Qbrexza and legacy products declined due to coverage mix and generic competition.
Operating expenses were broadly flat year over year for the quarter, with selling, general and administrative costs declining as Emrosi launch spending eased. The company recorded a small net loss of $0.3 million for the quarter versus a $3.8 million loss in the prior-year quarter, and a $2.5 million loss for the first half versus $7.9 million previously.
Cash and cash equivalents were $25.6 million and working capital was $27.0 million at June 30, 2026. Journey has a $25.0 million term loan outstanding under its SWK Credit Facility and an effective $150.0 million universal shelf registration. Despite better results, the company states that recurring and historical losses raise substantial doubt about its ability to continue as a going concern over the next twelve months.
Journey Medical Corporation reported second-quarter 2026 total revenue of $18.5 million, reflecting 23% growth from the prior-year quarter. Product revenue was $17.8 million and other revenue $0.7 million. Emrosi® contributed $8.1 million in revenue as prescription demand and payer coverage increased.
Income from operations was $0.5 million, compared with a $2.9 million operating loss a year earlier, while net loss narrowed to $0.3 million from $3.8 million. Non-GAAP Adjusted EBITDA turned positive at $2.9 million versus a loss of $0.5 million in the prior-year quarter. As of June 30, 2026, cash and cash equivalents were $25.6 million, total assets were $98.4 million, and stockholders’ equity was $32.1 million.
Vanguard Capital Management filed an amended Schedule 13G reporting beneficial ownership of 774,556 shares of Journey Medical Corp common stock, representing 3.59% of the class. This reflects securities beneficially owned or deemed owned by Vanguard Capital Management LLC and specified affiliated entities and business divisions.
Vanguard has sole voting power over 99,371 shares and sole dispositive power over 774,556 shares, with no shared voting or dispositive power. Vanguard and its managed funds and accounts may receive dividends or proceeds from these securities, but no other single person’s interest exceeds 5% of the class.
Wasatch Advisors filed Amendment No. 3 to a Schedule 13G reporting beneficial ownership of 2,858,930 shares of Journey Medical Corp common stock, representing 13.3% of the class. The shares are held with sole power to dispose and sole voting power over 2,664,647 shares, with no shared voting or dispositive authority.
Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Toledano Miranda Jayne received a grant of 50,000 shares of common stock in the form of restricted stock units on July 1, 2026 under the company’s 2015 Stock Plan. These RSUs vest in three annual installments: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030, and 16,667 shares on July 1, 2031.
Following this award, Toledano directly holds 168,618 shares of Journey Medical common stock, including restricted stock units that vest over various time periods. The grant reflects equity-based compensation rather than an open-market purchase.
Smith Justin Adam reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Justin Adam Smith received a grant of 50,000 restricted stock units as equity compensation. The award was granted on July 1, 2026 under Journey Medical Corp's 2015 Stock Plan, as amended. These restricted stock units vest over a long-term schedule: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030 and 16,667 shares on July 1, 2031, tying the director’s compensation to the company’s future performance. Following this grant, Smith directly holds a total of 231,618 shares and restricted stock units, which vest over various time periods.
Herskowitz Neil reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Neil Herskowitz received a grant of 50,000 restricted stock units (RSUs) of common stock as equity compensation. The grant was made on July 1, 2026 under the company’s 2015 Stock Plan and will vest over several years.
The RSUs vest in three tranches: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030, and 16,667 shares on July 1, 2031, if applicable conditions are met. After this award, Herskowitz’s direct holdings, including RSUs that vest over time, total 168,618 shares.
Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Miranda Jayne Toledano received an equity award of 10,000 shares of common stock in the form of restricted stock units. The grant was made on June 25, 2026 under the company’s 2015 Stock Plan, as amended.
The 10,000 restricted stock units are scheduled to vest in full on June 25, 2027, increasing her time-based incentive to remain aligned with shareholders. After this grant, Toledano’s direct holdings, including other restricted stock units that vest over various periods, total 118,618 shares of Journey Medical common stock.
Smith Justin Adam reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Justin Adam Smith received a grant of 10,000 shares of common stock as restricted stock units on June 25, 2026. These units were issued under the company’s 2015 Stock Plan and will vest as 10,000 shares on June 25, 2027.
After this equity award, Smith’s direct holdings total 181,618 shares, including restricted stock units that vest over various time periods. This is a compensation-related equity grant rather than an open-market share purchase or sale.
Herskowitz Neil reported acquisition or exercise transactions in this Form 4 filing.
Journey Medical Corp director Neil Herskowitz received a grant of 10,000 restricted stock units as equity compensation. The award was made under the company’s 2015 Stock Plan and will vest in full on June 25, 2027. Following this grant, Herskowitz’s direct holdings total 118,618 shares, including restricted stock units that vest over various periods.